TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Hansa Biopharma AB
Closing information (x1000 DKK)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover |
103,259
|
24,634
|
4,520 |
Financial expenses |
32,502
|
886
|
190 |
Earnings before taxes |
-407,608
|
-398,563
|
-311,949 |
EBITDA |
-393,314
|
-397,725
|
-307,686 |
Total assets |
1,127,581
|
736,444
|
1,063,192 |
Current assets |
1,072,317
|
685,206
|
1,032,724 |
Current liabilities |
176,891
|
124,499
|
84,643 |
Equity capital |
402,885
|
550,855
|
920,613 |
- share capital |
36,776
|
33,692
|
30,720 |
Employees (average) |
144
|
116
|
82 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency |
35.7%
|
74.8%
|
86.6% |
Turnover per employee |
717
|
212
|
55 |
Profit as a percentage of turnover |
-394.7%
|
-1617.9%
|
-6901.5% |
Return on assets (ROA) |
-33.3%
|
-54.0%
|
-29.3% |
Current ratio |
606.2%
|
550.4%
|
1220.1% |
Return on equity (ROE) |
-101.2%
|
-72.4%
|
-33.9% |
Change turnover |
80,620
|
20,200
|
2,026 |
Change turnover % |
356%
|
456%
|
81% |
Chg. No. of employees |
28
|
34
|
19 |
Chg. No. of employees % |
24%
|
41%
|
30% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.